ArticleBlood cells, molecules & diseases2011
Ex vivo rapamycin treatment of human cord blood CD34+ cells enhances their engraftment of NSG mice.
Article in Blood cells, molecules & diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 38 citations in OpenAlex.
- Article
- Hematopoietic (stem) cells-The elixir of life?FEBS letters · 2026Review
- Mitofusin agonists enhances long-term engraftment and potency of HSC culturesbioRxiv : the preprint server for biology · 2025Article
- Insights into highly engraftable hematopoietic cells from 27-year cryopreserved umbilical cord blood.Cell reports. Medicine · 2023Article
- Review
- Article
- The Role of Nutrients in Maintaining Hematopoietic Stem Cells and Healthy Hematopoiesis for Life.International journal of molecular sciences · 2022Review
- mTOR Signaling as a Regulator of Hematopoietic Stem Cell Fate.Stem cell reviews and reports · 2021Review
- Successfully transfected primary peripherally mobilized human CD34+ hematopoietic stem and progenitor cells (HSPCs) demonstrate increased susceptibility to retroviral infection.Virology journal · 2020Article
- mTOR inhibitors lower an intrinsic barrier to virus infection mediated by IFITM3.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Ex Vivo Expansion of CD34Stem cells translational medicine · 2018Article
- Role of mTORC1-S6K1 signaling pathway in regulation of hematopoietic stem cell and acute myeloid leukemia.Experimental hematology · 2017Review
- Cord Blood Cells Responses to IL2, IL7 and IL15 Cytokines for mTOR Expression.Advanced pharmaceutical bulletin · 2017Article
- Pharmacological inhibition of AKT activity in human CD34Experimental hematology · 2017Article
- Article
- Article
- Role of the mammalian target of rapamycin pathway in lentiviral vector transduction of hematopoietic stem cells.Current opinion in hematology · 2015Review
- [Rapamycin decreases irradiation-induced hematopoietic system damage].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2015Article
- Cyclosporin a and rapamycin relieve distinct lentiviral restriction blocks in hematopoietic stem and progenitor cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Article
- Modeling promising nonmyeloablative conditioning regimens in nonhuman primates.Human gene therapy · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Since cord blood (CB) has become a commonly used source of transplantable hematopoietic stem (HSC) and hematopoietic progenitor cells (HPC), there has been a need to overcome the limited HSC and HPC numbers available to transplant from a single CB, especially for adult recipients. Our laboratory previously demonstrated that Rheb2 overexpression significantly impaired the repopulating ability of HSC. Since overexpression of Rheb2 leads to increased signaling through mTOR, we examined the effect of the mTOR inhibitor rapamycin ex vivo on cytokine expanded CD34(+) CB cells for the engraftment of these cells in non-obese diabetic, severe combined immunodeficient, IL-2 receptor γ chain null (NSG) mice. We observed significant enhancement in engraftment of the CB treated ex vivo with cytokines in the presence of rapamycin prior to transplant, effects seen in primary as well as secondary transplants. These pre-clinical results suggest a positive role for rapamycin during ex vivo culture of CB SCID repopulating cells/HSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.